NASDAQ:ABOS - Nasdaq - US00509G2093 - Common Stock - Currency: USD
0.9801
-0.02 (-1.99%)
The current stock price of ABOS is 0.9801 USD. In the past month the price decreased by -3.91%. In the past year, price decreased by -70.83%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.97 | 326.55B | ||
AMGN | AMGEN INC | 12.81 | 142.94B | ||
GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
NTRA | NATERA INC | N/A | 20.66B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
BIIB | BIOGEN INC | 7.47 | 17.32B |
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Charlottesville, Virginia and currently employs 61 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The firm is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.
ACUMEN PHARMACEUTICALS INC
427 Park St.
Charlottesville VIRGINIA US
CEO: Daniel O'Connell
Employees: 61
Phone: 19253688508
The current stock price of ABOS is 0.9801 USD. The price decreased by -1.99% in the last trading session.
The exchange symbol of ACUMEN PHARMACEUTICALS INC is ABOS and it is listed on the Nasdaq exchange.
ABOS stock is listed on the Nasdaq exchange.
12 analysts have analysed ABOS and the average price target is 9.38 USD. This implies a price increase of 857.45% is expected in the next year compared to the current price of 0.9801. Check the ACUMEN PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ACUMEN PHARMACEUTICALS INC (ABOS) has a market capitalization of 59.36M USD. This makes ABOS a Micro Cap stock.
ACUMEN PHARMACEUTICALS INC (ABOS) currently has 61 employees.
ACUMEN PHARMACEUTICALS INC (ABOS) has a resistance level at 1. Check the full technical report for a detailed analysis of ABOS support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ABOS does not pay a dividend.
ACUMEN PHARMACEUTICALS INC (ABOS) will report earnings on 2025-05-20, before the market open.
ACUMEN PHARMACEUTICALS INC (ABOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.71).
The outstanding short interest for ACUMEN PHARMACEUTICALS INC (ABOS) is 3.29% of its float. Check the ownership tab for more information on the ABOS short interest.
ChartMill assigns a fundamental rating of 1 / 10 to ABOS. ABOS has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ABOS reported a non-GAAP Earnings per Share(EPS) of -1.71. The EPS decreased by -58.33% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -42.82% | ||
ROE | -56.28% | ||
Debt/Equity | 0.16 |
ChartMill assigns a Buy % Consensus number of 87% to ABOS. The Buy consensus is the average rating of analysts ratings from 12 analysts.